Status:

TERMINATED

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Lead Sponsor:

Bassett Healthcare

Collaborating Sponsors:

Reid Health

Goshen Health System

Conditions:

SARS-CoV-2 Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion...

Detailed Description

Although a number of therapeutics have been utilized by clinicians to treat hospitalized patients with COVID-19, none were systematically evaluated in clinical trials at the time of the outset of this...

Eligibility Criteria

Inclusion

  • Inclusion criteria
  • Hospitalized patient
  • Age \>= 18 years
  • Able to ingest oral medication or be administered medication via gastric tube or equivalent
  • Laboratory confirmation of SARS-CoV-2 infection within 1 week prior to randomization
  • Randomization within 72 hr of hospital admission
  • Negative pregnancy test for reproductive age women
  • Patient or LAR able to provide informed consent
  • Exclusion criteria
  • Allergy or intolerance to losartan or other ARBs
  • Already taking ACE or ARB (within 1 month)
  • Hypotension at time of enrollment (SBP \< 100 mm Hg)
  • Hyperkalemia (K \>/= 5.0 at time of screening or history of hyperkalemia)
  • Severe renal dysfunction (estimated GFR \< 30 ml/min at time of screening or history advanced renal disease)
  • Severe volume depletion or acute kidney injury (AKI) at time of enrollment
  • Known cirrhotic ascites
  • Known severe aortic or mitral valve stenosis
  • Known unstented renal artery stenosis
  • Co-administration with certain drugs due to CYP3A interactions if taken in \< 24 hr
  • Severe hepatic insufficiency (LFTs \> 5 times the upper limit of normal or known ESLD or cirrhosis)
  • Nausea/vomiting or aspiration risk precluding oral medications unless can be given by gastric tube
  • Pregnancy or breast feeding
  • Absence of dependable contraception in reproductive age women
  • Inability to obtain or declined informed consent

Exclusion

    Key Trial Info

    Start Date :

    April 6 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2021

    Estimated Enrollment :

    15 Patients enrolled

    Trial Details

    Trial ID

    NCT04328012

    Start Date

    April 6 2020

    End Date

    December 1 2021

    Last Update

    March 24 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Bassett Medical Center

    Cooperstown, New York, United States, 13326